Abstract：
This review highlights the potential mechanisms of neuromuscular manifestation of COVID-19, especially myasthenia gravis (MG).
An extensive literature search was conducted by two independent investigators using PubMed/MEDLINE and Google Scholar from its inception to December 2020.
Exacerbations of clinical symptoms in patients of MG who were treated with some commonly used COVID-19 drugs has been reported, with updated recommendations of management of symptoms of neuromuscular disorders. Severe acute respiratory syndrome coronavirus 2 can induce the immune response to trigger autoimmune neurological disorders.
Further clinical studies are warranted to indicate and rather confirm if MG in the setting of COVID-19 can pre-existent subclinically or develop as a new-onset disease.
An extensive literature search was conducted by two independent investigators using PubMed/MEDLINE and Google Scholar from its inception to December 2020.
Exacerbations of clinical symptoms in patients of MG who were treated with some commonly used COVID-19 drugs has been reported, with updated recommendations of management of symptoms of neuromuscular disorders. Severe acute respiratory syndrome coronavirus 2 can induce the immune response to trigger autoimmune neurological disorders.
Further clinical studies are warranted to indicate and rather confirm if MG in the setting of COVID-19 can pre-existent subclinically or develop as a new-onset disease.
摘要：
背景：这篇综述强调了COVID-19神经肌肉表现的潜在机制，尤其是重症肌无力（MG）。
方法：从成立到2020年12月，由两名独立研究者使用PubMed/MEDLINE和GoogleScholar进行了广泛的文献检索。
结果：据报道，接受一些常用COVID-19药物治疗的MG患者的临床症状加重，关于神经肌肉疾病症状管理的最新建议。严重急性呼吸综合征冠状病毒2可诱导免疫反应引发自身免疫性神经系统疾病。
结论：有必要进行进一步的临床研究，以表明并确认COVID-19中的MG是否可以预先存在亚临床或发展为新发疾病。
方法：从成立到2020年12月，由两名独立研究者使用PubMed/MEDLINE和GoogleScholar进行了广泛的文献检索。
结果：据报道，接受一些常用COVID-19药物治疗的MG患者的临床症状加重，关于神经肌肉疾病症状管理的最新建议。严重急性呼吸综合征冠状病毒2可诱导免疫反应引发自身免疫性神经系统疾病。
结论：有必要进行进一步的临床研究，以表明并确认COVID-19中的MG是否可以预先存在亚临床或发展为新发疾病。
